Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
NCT ID: NCT05888662
Last Updated: 2025-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2023-10-23
2029-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
First described in 1996, epicardial ablation, performed via a percutaneous subxyphoid approach, has since undergone considerable development. Electrophysiologists often use a double endo- and epicardial approach as first line therapy for the ablation of VTs complicating myocarditis or arrhythmogenic dysplasia of the right ventricle, where the substrate is most often epicardial.
For VT in ischaemic heart disease, electrophysiologists perform endocardial ablation, and often perform epicardial ablation only after several endocardial failures. Several observational studies suggest that a combined endo- and epicardial approach as first line therapy is associated with a reduced risk of VT recurrence. Since recurrent VT in patients with ischaemic heart disease as a prognostic impact in terms of morbidity and mortality, it appears essential to optimise rhythm management by ablation, by offering a combined approach from the as first approach to reduce the risk of recurrences.
The aim of our prospective, multicentre, controlled, randomized study is therefore to compare the rate of VT recurrence after ablation performed as first line therapy either by endocardial approach alone or by combined endo-epicardial approach.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy
NCT00905853
Complex Arrhythmia Registry
NCT07024927
Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy
NCT04512911
Does Timing of VT Ablation Affect Prognosis in Patients With an Implantable Cardioverter-defibrillator?
NCT01547208
VT Ablation in the iCMR
NCT05543798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endo-epicardial ablation
Endo-epicardial ablation
Endo-epicardial ablation of ventricular tachycardia
endocardial ablation only
endocardial ablation only
endocardial-only catheter ablation of ventricular tachycardia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endo-epicardial ablation
Endo-epicardial ablation of ventricular tachycardia
endocardial ablation only
endocardial-only catheter ablation of ventricular tachycardia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 1st radiofrequency ablation of VT complicating ischaemic heart disease
3. Patients with an ICD and remote monitoring
4. Having, for women of childbearing age, effective contraception until discharge from hospital
5. Have given their free and informed consent in writing
6. are affiliated to or have health insurance
Exclusion Criteria
2. Presence of a left intraventricular thrombus found during pre-procedure imaging
3. Anticoagulant therapy that cannot be temporarily discontinued
4. Double antiplatelet therapy that cannot be temporarily replaced by single antiplatelet therapy
5. History of pericarditis
6. Previous thoracic radiotherapy
7. Contraindication to general anaesthesia
8. Pregnant or breastfeeding woman
9. History of heparin-induced thrombocytopenia type 2 (as injection is required during the procedure)
10. Person under legal protection (safeguard of justice, curatorship, guardianship), deprived of liberty, or unable to express consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raphaël MARTINS, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeaux
Bordeaux, , France
Centre Hospitalier Universitaire de Caen
Caen, , France
Centre Hospitalier de Clermont-Ferrand
Clermont-Ferrand, , France
Centre Hospitalier Régional Universitaire de Lille
Lille, , France
Hospices Civils de Lyon
Lyon, , France
CHU de Nantes
Nantes, , France
Hôpital Européen Georges Pompidou
Paris, , France
Hôpital Universitaire La Pitié-Salpêtrière - Paris
Paris, , France
CHU de Rennes
Rennes, , France
Centre Hospitalier Universitaire de Saint-Étienne
Saint-Etienne, , France
Centre Hospitalier Universitaire Toulouse - Hôtel Dieu Saint-Jacques
Toulouse, , France
Centre Hospitalier Régional Universitaire Tours - Hôpital Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Frédéric SACHER
Role: primary
Laure CHAMP RIGOT
Role: primary
Grégoire MASSOUILLIE
Role: primary
François BRIGADEAU
Role: primary
Françis BESSIERE
Role: primary
Jean-Baptiste GOURRAUD
Role: primary
Xavier WAINTRAUB
Role: primary
Raphaël MARTINS
Role: primary
Jean-Philippe MAURY
Role: primary
Bertrand PIERRE
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC20_9765_EPIC-VT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.